MedTrace Logo

DCEP in Combination With Thalidomide as Salvage Therapy for Post Transplantation Relapse

NCT00083681 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2010-07-02

No results posted yet for this study

Summary

The purpose of this investigational trial is to find out how well patients respond and how long their response lasts when treated with a four day chemotherapy regimen involving dexamethasone, cytoxan, etoposide, and cisplatinum, or DCEP with or without thalidomide. Another purpose is to find out what kind of side effects patients will experience.

Conditions

Interventions

DRUG

Thalidomide

DRUG

Dexamethasone

DRUG

Cytoxan

DRUG

Etoposide

DRUG

Cisplatin

DRUG

G-CSF

Sponsors & Collaborators

  • University of Arkansas

    lead OTHER

Principal Investigators

  • Athanasios Fassas, M.D. · UAMS

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-06-30
Completion
2005-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00083681 on ClinicalTrials.gov